Phaseline

Targets › TCRB

TCRB: drug programs, companies and trials

3 programs from 3 companies in 5 trials: 3 Phase 2, 2 Phase 1; Hematology, Metabolic and endocrine, Oncology; next expected readout Jan 2027.

Open in Phaseline: the race on TCRB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Masonic Cancer Center, University of MinnesotaT cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC)
Selective depletion of T cells expressing TCR alpha/beta to reduce graft-versus-host disea
TCRA, TCRBPhase 2Fanconi AnemiaJan 2027
Johns Hopkins All Children's HospitalTCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
TCR alpha beta T-cell and CD19 B-cell depleted haploidentical hematopoietic cell transplan
TCRA, TCRB, CD19Phase 2Hemoglobinopathy (Disorder); Primary Immune Deficiency DisordersJun 2027
Marengo TherapeuticsSTAR0602
Selective TCR-targeting bifunctional antibody-fusion molecule
TCRA, TCRBPhase 1Triple Negative Locally Advanced Non-resectable Breast Cancer; Advanced Solid TumorsJan 2027

Conditions

Hemoglobinopathy (Disorder) (1) Primary Immune Deficiency Disorders (1) Fanconi Anemia (1) Triple Negative Locally Advanced Non-resectable Breast Cancer (1) Advanced Solid Tumors (1)

Modalities

other (1), mixed (1), small molecule (1)

Companies

Johns Hopkins All Children's Hospital (1) Masonic Cancer Center, University of Minnesota (1) Marengo Therapeutics (1)

Related targets

TCRA (3) CD19 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.